Category Archives: Deals

Uzum figure pour la première fois parmi les meilleures sociétés mondiales du secteur de la fintech selon CNBC et Statista

Uzum, écosystème numérique national de l’Ouzbékistan, figure pour la première fois dans le classement World’s Top Fintech Companies 2026, établi par CNBC en partenariat avec Statista, société internationale spécialisée dans les études de marché et l’analyse de données. Uzum a été récompensée dans la catégorie « Neobanking ».

TASHKENT, Ouzbékistan, 22 juillet 2026 — Le classement des meilleures sociétés mondiales de la fintech établi par CNBC et Statista est l’une des références mondiales les plus respectées du secteur. Ce prix distingue les entreprises qui façonnent l’avenir des services financiers grâce à la technologie, à l’innovation et à des solutions numériques évolutives. La catégorie « Neobanking » regroupe les prestataires de services financiers numériques de nouvelle génération qui proposent des services bancaires et assimilés principalement via des canaux numériques, sans passer par les réseaux d’agences traditionnels.

Le fait qu’Uzum figure parmi les principales entreprises mondiales du secteur de la fintech témoigne de la confiance croissante que des millions d’utilisateurs accordent à ses solutions financières numériques. En Ouzbékistan, de plus en plus de personnes ont recours aux services numériques pour effectuer leurs paiements quotidiens, leurs achats, assurer la gestion de leurs finances personnelles et accéder aux services bancaires.

« Cette distinction témoigne avant tout du fait qu’une approche écosystémique est en train de transformer le quotidien financier de millions de personnes. Nous mettons en place un écosystème évolutif qui offre une expérience utilisateur fluide, dans lequel les services financiers et les services de tous les jours sont intégrés au sein d’un environnement unique. Cela permet aux utilisateurs d’accéder plus facilement aux solutions dont ils ont besoin, tout en nous permettant d’élargir en permanence notre gamme de produits et de proposer des services numériques modernes dans tout le pays. Cette approche a déjà incité plus de 6 millions d’utilisateurs à opter pour les cartes Uzum Bank, celles-ci étant désormais intégrées de manière naturelle dans les interactions quotidiennes au sein de l’écosystème, bien au-delà de leur simple fonction d’instrument de paiement. Nous créons une expérience numérique simplifiée dans laquelle les services financiers s’intègrent naturellement dans la vie quotidienne, permettant ainsi aux utilisateurs de faire leurs achats, d’effectuer des paiements, d’accéder à des financements à crédit, d’effectuer des virements et d’utiliser d’autres services au sein d’un même écosystème, en quelques clics seulement.

En alliant technologie, facilité d’utilisation et modèle fondé sur un écosystème, nous sommes en mesure de développer rapidement nos services, d’élargir l’accès aux solutions financières numériques, de créer de nouvelles opportunités pour les entrepreneurs grâce à la finance intégrée et de contribuer au développement de l’économie numérique de l’Ouzbékistan », a déclaré  Djasur Djumaev, PDG et fondateur d’Uzum.

Ce classement repose sur la méthodologie d’évaluation exhaustive de Statista, qui associe des indicateurs généraux de performance d’entreprise à des indicateurs clés de performance (KPI) spécifiques à chaque segment du secteur de la fintech. Cette approche permet d’évaluer les entreprises non seulement en fonction de leur taille, mais aussi en fonction de leurs performances opérationnelles, de leur trajectoire de croissance et de leur niveau de maturité numérique.

StrongestLayer Reaches $9.3M in Total Seed Funding to Stop the AI-Era Email Attacks Legacy Defenses Cannot See

New round led by Inovia Capital backs a reasoning-based architecture designed for attacks that bypass traditional email security

SAN FRANCISCO, July 22, 2026 — StrongestLayer, the AI-native email security company, today announced it has raised $4.1 million in new funding, bringing total seed funding to $9.3 million. The round was led by Inovia Capital with participation from existing investor Sorenson Capital, and new investors LaunchPod, Alumni Ventures, and Chris Key, former Chief Product Officer of Mandiant.

The funding follows a year of rapid product and customer growth as enterprises confront a new generation of email threats that increasingly evade traditional detection methods.

Since launching, StrongestLayer has experienced rapid product and customer momentum, with production deployments growing more than eightfold since the company announced its initial funding twelve months ago.

The new funding will support continued investment in GTM and platform expansion as the company prepares for its next phase of growth and a planned Series A.

The Attacks Email Security Was Not Built to Stop

StrongestLayer analyzed thousands of detections across enterprise environments between December 2025 and February 2026 and found that more than one-third of attacks reaching inboxes cannot be reliably detected using the pattern-matching and behavioral techniques that underpin most existing email security platforms.

Many of the attacks causing the most damage today bypass the signals that email security products have historically relied on to make detection decisions. These attacks look legitimate on the surface. Some steal authenticated sessions after users successfully log in. Others are delivered through trusted platforms and services that pass authentication checks. Increasingly, business email compromise, executive impersonation, and vendor fraud schemes contain no malicious links or attachments at all, relying instead on persuasive language and social engineering.

“Every generation of email security was built to recognize attacks it had seen before,” said Alan LeFort, co-founder and CEO of StrongestLayer. “That worked when attackers reused templates and infrastructure. It does not work when every attack is unique. We didn’t build a better filter. We built a system that reasons about whether a message is legitimate and whether it intends harm.”

Moving Beyond Pattern Matching

Instead of relying on signatures, reputation databases, or historical attack patterns, StrongestLayer uses a reasoning-based architecture designed to investigate intent. The platform builds arguments for legitimacy and maliciousness, then weighs the evidence before reaching a verdict. Because the system reasons against the context of the organization it protects, it does not depend on having seen an attack before to identify it.

Within months of its first release, StrongestLayer has won multiple competitive evaluations against both legacy secure email gateways and newer platforms claiming to be “AI-powered” by consistently identifying attacks those systems missed.

“We led this round because StrongestLayer achieved incumbent-displacing capability with a fraction of the capital many companies in this category required simply to get to market,” said Taha Mubashir, Partner at Inovia Capital. “The team is demonstrating what becomes possible when AI is the foundation of the architecture rather than an enhancement layered onto older approaches.”

“We invest in teams that build smarter, and StrongestLayer is a clear example of that philosophy,” said Ken Elefant, Managing Partner at Sorenson Capital. “Alan and his team have woven AI into the fabric of StrongestLayer, from product development to go-to-market, creating a capital-efficient engine purpose-built for today’s threat landscape. Legacy email security tools weren’t built to catch today’s AI-generated attacks, and StrongestLayer identified that gap, delivering a comprehensive solution to customers.”

“Having spent years evaluating whether security controls actually stop real attacks, I believe StrongestLayer is taking the right architectural approach for where email security is headed,” said Chris Key, former Chief Product Officer of Mandiant and an investor in StrongestLayer. “Attackers are moving beyond reusable templates, known infrastructure, and obvious payloads. Defenders need systems that can reason through intent and business context, and that is what makes StrongestLayer so compelling.”

StrongestLayer’s threat research, including its taxonomy of 44 email attack subtypes and the detection framework behind these findings, is available to the security community at tools.strongestlayer.org.

About StrongestLayer

StrongestLayer is the AI-native email security company founded in 2024. Its reasoning-based platform detects and stops advanced phishing, adversary-in-the-middle attacks, and business email compromise by analyzing the intent and business context of a message rather than matching it against known patterns. The company is based in San Francisco. Learn more at strongestlayer.com.

About Inovia Capital

Inovia Capital is Canada’s leading multi-stage software investor, partnering with founders to build impactful and enduring global companies. With three investment strategies—Discovery, Venture, and Growth—the team leverages an operator-led mindset to provide founders with multi-stage support, mentorship, and access to a worldwide network. Inovia manages over USD $2.5B with operations in Montreal, Toronto, Waterloo, Calgary, Bay Area, London and Abu Dhabi. For more information, visit inovia.vc.

SOURCE StrongestLayer

Connecticut Innovations Generates Record $66.5 Million in Proceeds in FY2026

Landmark exits, including the largest private biotech M&A deal on record, drove returns that CI will reinvest in Connecticut’s innovation economy

NEW HAVEN, Conn., July 22, 2026 — Connecticut Innovations (CI), the state’s strategic venture capital arm, today announced a record-breaking fiscal year, generating $66.5 million in cash proceeds from a series of landmark portfolio exits and a combined $76.1 million from all investment activities. CI invested $59.3 million in 75 early-stage companies and venture funds during the fiscal year ending June 30, 2026, with those deals leveraging an additional $1.2 billion in outside capital.

This fiscal year’s proceeds were driven by several significant portfolio exits, including but not limited to:

  • Halda Therapeutics (Acquired by Johnson & Johnson for $3.05 billion)
  • Quantum Circuits Inc. (Acquired by D-Wave Quantum for $550 million)
  • Veradermics (NYSE IPO; raised $256.3 million)

“This was a landmark year for Connecticut Innovations and for the state’s innovation economy,” said Matt McCooe, CEO of Connecticut Innovations. “The success of Halda Therapeutics and Veradermics—respectively becoming the largest private biotech M&A transaction and the best-performing biotech IPO in the market at the time—demonstrates the trajectory New Haven and Connecticut are on as they continue to emerge as global leaders in life sciences innovation.”

Throughout the fiscal year, CI continued to build on its role as a catalyst for Connecticut’s venture ecosystem through initiatives including the third annual Tour de Connecticut, a statewide bike ride showcasing innovation across the state; the second annual Talent Fair, connecting the next generation of innovators with CI portfolio companies eager to hire; and the launch of its AI/Q Fund, targeting scalable commercial AI and quantum ventures.

“The acquisition of Quantum Circuits Inc. marks an exciting milestone for Connecticut’s quantum ecosystem and reinforces the opportunity we see every day through our AI/Q Fund,” said Gwen Cheni, director of the AI/Q Fund. “We’re already investing in exceptional founders building AI and quantum companies, and we believe this is just the beginning of a new wave of innovation that will create lasting economic impact for the state.”

About Connecticut Innovations
Connecticut Innovations (CI) is Connecticut’s strategic venture capital arm and the leading source of financing and ongoing support for innovative, growing companies. By offering equity and debt investments, strategic guidance and introductions to valuable partners, CI helps promising businesses thrive. For more information, visit http://www.ctinnovations.com.

Media Contact:
Lauren Carmody
Connecticut Innovations
860.258.7829
[email protected]

SOURCE Connecticut Innovations

Uzum erstmals von CNBC und Statista zu einem der weltweit führenden Fintech-Unternehmen gekürt

Uzum, das nationale digitale Ökosystem Usbekistans, wurde erstmals in die Liste der weltweit führenden Fintech-Unternehmen 2026 aufgenommen, die von CNBC in Zusammenarbeit mit dem globalen Marktforschungs- und Analyseunternehmen Statista erstellt wurde. Uzum wurde in der Kategorie „Neobanking” ausgezeichnet.

TASCHKENT, Usbekistan, 22. Juli 2026 — Die von CNBC und Statista erstellte Liste der weltweit führenden Fintech-Unternehmen zählt zu den renommiertesten globalen Benchmarks der Branche. Sie würdigt Unternehmen, die mit Technologie, Innovation und skalierbaren digitalen Lösungen die Zukunft der Finanzdienstleistungen gestalten. Die Kategorie „Neobanking” umfasst Anbieter digitaler Finanzdienstleistungen der nächsten Generation, die Bankdienstleistungen und bankähnliche Dienstleistungen vorwiegend über digitale Kanäle erbringen, ohne auf traditionelle Filialnetze zurückzugreifen.

Die Aufnahme von Uzum in den Kreis der weltweit führenden Fintech-Unternehmen spiegelt das wachsende Vertrauen wider, das Millionen von Nutzern in die digitalen Finanzlösungen des Unternehmens setzen. Immer mehr Menschen in ganz Usbekistan nutzen digitale Dienste für alltägliche Zahlungen, Einkäufe, die Verwaltung ihrer privaten Finanzen und den Zugang zu Bankdienstleistungen.

„Diese Anerkennung ist vor allem ein Beleg dafür, dass ein ökosystemorientierter Ansatz das tägliche Finanzleben von Millionen von Menschen verändert. Wir bauen ein Ökosystem auf, das dank einer nahtlosen Benutzererfahrung skalierbar ist und Finanz- und Alltagsdienstleistungen in einer einzigen Umgebung vereint. Dies erleichtert den Nutzern den Zugang zu den Lösungen, die sie benötigen, und ermöglicht es uns gleichzeitig, unser Produktangebot kontinuierlich zu erweitern und moderne digitale Dienste landesweit zur Verfügung zu stellen. Dieser Ansatz hat bereits dazu geführt, dass sich mehr als 6 Millionen Nutzer für Karten der Uzum Bank entschieden haben, da die Karte mittlerweile ein selbstverständlicher Bestandteil des täglichen Umgangs mit dem Ökosystem ist und nicht mehr nur ein Zahlungsmittel darstellt. Wir schaffen ein nahtloses digitales Erlebnis, bei dem Finanzdienstleistungen in den Alltag integriert sind, sodass Nutzer innerhalb eines einzigen Ökosystems mit nur wenigen Klicks einkaufen, bezahlen, Ratenfinanzierungen nutzen, Geld überweisen und weitere Dienste in Anspruch nehmen können.

Durch die Kombination von Technologie, Komfort und einem ökosystembasierten Modell können wir unsere Dienstleistungen rasch ausbauen, den Zugang zu digitalen Finanzlösungen erweitern, durch Embedded Finance neue Möglichkeiten für Unternehmer schaffen und zur Entwicklung der digitalen Wirtschaft Usbekistans beitragen”, so Djasur Djumaev, CEO und Gründer von Uzum.

Die Liste basiert auf der umfassenden Bewertungsmethodik von Statista, die allgemeine Kennzahlen zur Unternehmensleistung mit kategoriespezifischen Leistungskennzahlen kombiniert, die auf die einzelnen Fintech-Segmente zugeschnitten sind. Dieser Ansatz ermöglicht es, Unternehmen nicht nur anhand ihrer Größe, sondern auch anhand ihrer operativen Leistung, ihrer Wachstumsentwicklung und ihres Grades an digitaler Reife zu bewerten.

Passionfroot Raises $15M Series A Led by Insight Partners to Power Creator-Led Growth in the AI Era

  • $15M Series A led by Insight Partners (Anthropic, Shopify, Twitter, Wiz)
  • 13x revenue growth in a year, profitable, with a team of 15
  • Powers creator-led growth across 20+ B2B verticals – financial services, coding, marketing, design – for the most forward-leaning companies, including ElevenLabs, Figma, Replit, Framer and Gamma
  • Co-founder and CEO Jen Phan relocating to New York to open NY office
  • Expanding talent base across US and Europe

NEW YORK and BERLIN, July 22, 2026 — Passionfroot, the platform for B2B creator-led growth, today announced a $15M Series A led by Insight Partners, with participation from existing investors Creandum, Supernode Global, and s16vc. Passionfroot is the first AI-native platform for B2B creator-led growth, built for a moment when traditional channels are losing effectiveness and buyers increasingly discover software through independent voices they already trust. The company handles everything from creator discovery to contract, campaign execution to global payment, with AI unifying the process from end-to-end.

Zest, Passionfroot’s AI agent, executes creator campaigns from brief to payment. It’s powered by the Creator Graph, a proprietary dataset of B2B creator pricing and performance built from thousands of campaigns. Global payouts flow through the Passionfroot Wallet, giving brands visibility into creator spend that the category has historically lacked.

Built for B2B, not B2C

Passionfroot isn’t built for lifestyle creators or consumer ad buys; it’s for the hardest customers in software. The fastest-scaling, most demanding companies facing the defining question of the AI era: when anyone can build the product, how do you cut through and win mindshare? In that world, distribution matters more than ever, and those are exactly the companies Passionfroot is built for.

That extends to how Passionfroot is built. It’s AI-native in its operations, not just its product, which is how 15 people deliver at this scale.

Profitable hypergrowth

Over the past year Passionfroot grew revenue 13x while staying profitable with a team of 15. The customer list is the tell: ElevenLabs, Figma, Replit, Framer and Gamma, a roster heavy with AI-native companies that treat creators as core go-to-market from day one. Passionfroot’s creator platform spans thousands of independent voices across software, AI, developer tools and enterprise productivity, sectors that account for the majority of the company’s customer base.

“With Passionfroot, we’ve been able to build and scale our creator program in a way that wasn’t possible before. In the age of AI, you need to reach your buyers through voices they already trust – and Passionfroot makes that scalable. What used to take weeks now happens in days. It’s become a core part of how we reach our community and tell better stories faster across channels.” (Alex Lin, Growth Marketing at Replit)

Why Insight backed it

Insight Partners, roughly $90B under management, backing Anthropic, Shopify, Twitter, Linktree, Wiz.

“AI-native companies are bringing a consumer playbook to B2B go-to-market. More and more, they’re scaling through creators their audiences already trust, and as generative engines reshape search, authentic user-generated content is becoming increasingly valuable. Passionfroot built the infrastructure for this shift: a platform that runs the entire creator campaign workflow end-to-end, with a data layer that gets smarter with every campaign. We’re thrilled to partner with Passionfroot as they define the category,” said Rebecca Liu-Doyle, Managing Director at Insight Partners.

What’s next

The funding will go toward making their AI Agent Zest run more of every campaign, deepening the Creator Graph, and scaling GTM in the US. Co-founder and CEO Jen Phan is relocating to New York to lead that expansion, while product and engineering stay anchored in Berlin and the company will be opening a third office in São Paulo for customer success and engineering. Passionfroot is hiring across all three.

“We’re entering the era of the B2B creator economy, and it’s moving faster than anyone expected,” said Jen Phan, Co-founder and CEO of Passionfroot. “The more AI floods the world with content, the more the trusted human voices – the domain experts and tastemakers people actually listen to – matter. Our job is to make reaching them as measurable and scalable as paid search became fifteen years ago.

About Passionfroot

Passionfroot is the AI-native platform for B2B creator-led growth. Its agent, Zest, runs creator campaigns end to end, powered by the proprietary Creator Graph and the Passionfroot Wallet for global payouts and attribution. The company works with 150+ B2B brands – including ElevenLabs, Figma, Replit, Framer and Gamma – and thousands of the world’s most influential creators. Founded in 2022 by Jen Phan and Lorenzo De Nobili and backed by Insight Partners, Creandum, Supernode Global, and s16vc. www.passionfroot.me

About Insight Partners

Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of December 31, 2025, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 900 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has a global presence with leadership in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

SOURCE Passionfroot

Groundfloor Lending Recognized by CNBC and Statista as One of the World’s Top Fintech Companies 2026

Award highlights company’s leadership in real estate financing

ATLANTA, July 22, 2026Groundfloor, the award-winning private market investing and lending platform, today announced it has been named one of CNBC and Statista’s World’s Top Fintech Companies, in the Alternative Financing category.

Now in its fourth year, the World’s Top Fintech Companies ranking recognizes 500 companies across eight market segments that are shaping the future of financial services through innovation and technology. Developed by CNBC and Statista, the ranking is based on a rigorous methodology that evaluates companies using a combination of key performance indicators.

“This recognition reflects our commitment to transforming how real estate entrepreneurs access capital,” said Brian Dally, co-founder and CEO of Groundfloor. “We’ve built a lending platform designed to deliver the speed, transparency, and reliability today’s investors need to compete in a fast-moving market. We’re proud that our approach to financing real estate projects is being recognized alongside the world’s most innovative fintech companies.”

Groundfloor Lending was recognized in the Alternative Financing category, which includes companies providing technology-driven, bank-independent financing solutions for individuals and businesses. Since 2013, Groundfloor Lending has loaned over $2.2 billion to real estate borrowers through its fix-and-flip, new construction, bridge, and DSCR products. Groundfloor Lending remains the only real estate lender to offer a truly deferred loan offering to qualified borrowers, allowing them to focus more on their renovation instead of monthly payments.

The recognition adds to a growing list of honors for Groundfloor, including being named to the Forbes Fintech 50, Benzinga’s Best Alternative Investment Platform, and the Inc. 5000 for six consecutive years. Earlier this year, Groundfloor Lending was also named a finalist in the IMN SFR Awards’ Best Fix-and-Flip Lender of the Year category, recognizing its leadership in financing residential real estate investors nationwide.

For more information about Groundfloor Lending and its financing solutions for real estate investors, visit groundfloorlending.com.

About Groundfloor
Groundfloor is an award-winning investing and lending company that unlocks institutional-grade private markets for investors and borrowers. Founded in 2013, the company pioneered retail access to private real estate debt. Today, Groundfloor continues to offer first-to-market real estate products such as Notes while expanding into a growing range of private markets, including consumer credit, small business finance, and music royalties. Recognized by Forbes Fintech 50 and the Inc. 5000 for six consecutive years, Groundfloor has facilitated more than $2.2 billion in investments across its private market offerings. Start investing or lending at Groundfloor.com.

Media Contact:
Hela Sheth
[email protected] 

SOURCE Groundfloor Finance Inc.

NTH CYCLE INC., A PURE PLAY CRITICAL MINERAL REFINING COMPANY, TO LIST ON NYSE THROUGH BUSINESS COMBINATION WITH KENSINGTON CAPITAL ACQUISITION CORP. VI

  • Nth Cycle will become a publicly traded company through a business combination with Kensington Capital Acquisition Corp. VI (NYSE: KCAC), with the combined company expected to trade on the NYSE under the ticker symbol “NTH”.
  • Nth Cycle fills one of the largest gaps in the critical mineral supply chain, onshoring the refining capability needed to curb Western dependence on China.
  • Nth Cycle’s proprietary electroextraction platform was built for Western markets, replacing the expense, build-out, and waste of traditional refineries with a faster, cheaper, and cleaner alternative.
  • Nth Cycle processes rare earth elements, copper, and battery materials—a trillion-dollar market driven by electrification, defense and AI infrastructure.
  • Proposed transaction implies a pro forma enterprise value of approximately $585 million.

BURLINGTON, Mass. and WESTBURY, N.Y., July 22, 2026 — Nth Cycle Inc. (“Nth Cycle” or the “Company”), a pure-play critical mineral refiner, and Kensington Capital Acquisition Corp. VI (“Kensington”) (NYSE: KCAC), a special purpose acquisition company, today announced a definitive business combination that will result in Nth Cycle becoming a publicly traded company. Upon closing of the transaction, the combined company will be named Nth Cycle Holdings, Inc., and its common stock is expected to trade on the NYSE under the new ticker symbol “NTH”.

Founded in 2017, Nth Cycle is building the refining capacity needed to secure Western critical mineral supply chains. Its OYSTER system converts the rare earth elements, copper, and battery metals found in mined and recycled materials into industrial-grade inputs for some of the world’s most strategic industries.

Nth Cycle’s Co-founder and CEO Dr. Megan O’Connor, commented: “Critical minerals are abundant across the West — but they have little to no commercial value until refined. That single chokepoint has left the United States, Europe, and allied nations entirely dependent on China, which has a tighter grip on these essential resources than OPEC ever had on oil. We’ve changed that with our modular refining system and are excited to partner with Kensington to scale our platform at the cost, speed, and efficiency Western markets demand.”

Kensington’s Chairman and CEO, Justin Mirro, added: “Kensington seeks partners who don’t just innovate — they redefine what’s possible for America’s future. Nth Cycle’s breakthrough OYSTER system is exactly that kind of transformative technology: a powerful, scalable solution that will secure our domestic critical minerals supply chain for the next century. We’ve spent years scaling companies in automotive and advanced manufacturing, so we know what it takes to move from breakthrough technology to large-scale commercial production. We’re really excited to partner with Megan and her outstanding team. Together, we’re going to help secure America’s critical minerals future and power the next generation of electrification, defense, and AI.”

Positioned for the Next Industrial Era, Aligned with Government Policy and Private Sector Demand

Critical minerals are one of the defining resources of the new industrial era, and like oil, they have no commercial value unless they are refined for end-use. China currently controls that purification for approximately 85% of the world’s mineral-rich materials, including those from the United States, Europe and allied nations. This bottleneck has become a national priority across the West, establishing refining capacity as a significant bridge to onshoring one of the most consequential supply chains of the next century.

Nth Cycle is currently focused on three fast-growing metal markets driven by federal policy and private sector demand: rare earths, the essential materials enabling military systems and advanced electronics; copper, irreplaceable for transmitting electricity, data and industrial power; and battery materials, which power energy storage, transportation, and electrification.

Nth Cycle’s commercial momentum includes operating the first U.S. refinery to produce high-purity nickel-cobalt mixed hydroxide product from recycled battery feedstock, a 10-year off-take term sheet with Trafigura valued at approximately $1.1 billion, and strategic development agreements with leading rare earth companies.

Transaction Overview

The business combination values Nth Cycle at an implied enterprise value of $585 million, assuming no redemptions by Kensington’s stockholders in connection with closing and the payment of estimated transaction expenses.

The board of directors of both Kensington and Nth Cycle have approved the proposed transaction, which is expected to be completed in the fourth quarter of 2026, subject to customary closing conditions, including regulatory and stockholder approvals.

Transaction proceeds to the combined company are expected to consist of up to $230 million in Kensington’s trust, subject to redemptions, and a common stock PIPE of up to $100 million, of which $40 million has to date been committed by new and existing investors. Additional information about the proposed transaction, including a copy of the Business Combination Agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by Kensington with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov.

Advisors

Hughes Hubbard & Reed LLP is serving as legal counsel to Kensington. Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, and Drexel Hamilton, LLC are acting as placement agents for Kensington. Latham & Watkins LLP is serving as legal counsel and Cantor Fitzgerald & Co. is acting as an exclusive financial advisor to Nth Cycle. Gateway Group is serving as investor relations and public relations advisor for the transaction.

About Nth Cycle Inc.

Nth Cycle is a critical minerals midstream refining company building the technology and infrastructure needed for Western supply chains. The company addresses the structural bottleneck of foreign dependence to process domestic critical mineral resources with its modular OYSTER system and proprietary electroextraction platform. Combined, they dramatically lower capital intensity, deployment time and emissions to convert industrial scrap, black mass and primary feeds into intermediate and refined products within the nickel, cobalt, copper and rare earth value chains. These advancements enable the domestic production and allied partnerships vital to industrial competitiveness, economic growth, and national security.

About Kensington Capital Acquisition Corp. VI

Kensington Capital Acquisition Corp. VI (NYSE: KCAC) is a special purpose acquisition company (SPAC) led by Chairman and Chief Executive Officer, Justin Mirro, Vice Chairman and President, Dieter Zetsche, Chief Operating Officer, Robert Remenar, Chief Technology Officer, Simon Boag and Chief Financial Officer, Daniel Huber. Kensington’s independent directors are William Kassling, Anders Pettersson, Mitchell Quain, Donald Runkle and Matthew Simoncini.

For more information about Kensington, please visit www.autospac.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain statements that are not historical facts but may be considered “forward-looking statements” within the meaning of Section 27(a) of the Securities Act of 1933 and Section 21(e) of the Securities Exchange Act of 1934. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the business combination, the estimated or anticipated future results and benefits of the combined company (“New Nth Cycle”) following the business combination (the “Business Combination”), including the likelihood and ability of the parties to successfully consummate the Business Combination, future opportunities for New Nth Cycle and other statements that are not historical facts.

These statements are based on the current expectations of the management of Kensington and/or Nth Cycle and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Kensington and Nth Cycle. These statements are subject to a number of risks and uncertainties regarding Nth Cycle’s business and the Business Combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions; the inability of the parties to consummate the Business Combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement (the “Business Combination Agreement”); the number of redemption requests made by shareholders of Kensington in connection with the Business Combination; the ultimate size of the PIPE conducted in connection with the Business Combination; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination; the risk that the approval of the shareholders of Nth Cycle or Kensington for the Business Combination is not obtained; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay in consummating the potential transaction; the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; the risks related to the rollout of the business of Nth Cycle and the timing of expected business milestones; the effects of competition on Nth Cycle’s business; the ability of New Nth Cycle to execute its growth strategy and secure sufficient capital to execute its growth strategy, manage growth profitably and retain its key employees; the ability of New Nth Cycle to obtain or maintain the listing of its securities on a U.S. national securities exchange following the Business Combination; costs related to the Business Combination; and other risks that will be detailed from time to time in filings with the SEC. The foregoing list of risk factors is not exhaustive. There may be additional risks that Kensington and Nth Cycle presently do not know or that Kensington and Nth Cycle currently believe are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Kensington’s and Nth Cycle’s expectations, plans or forecasts of future events and views as of the date of this press release. Kensington and Nth Cycle anticipate that subsequent events and developments will cause their assessments to change. However, while Kensington and Nth Cycle may elect to update these forward-looking statements in the future, Kensington and Nth Cycle specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Kensington’s or Nth Cycle’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or results of such forward-looking statements will be achieved. This press release contains preliminary information only, is subject to change at any time, and is not, and should not be assumed to be, complete or constitute all of the information necessary to adequately make an informed decision regarding any potential investment in connection with the Business Combination.

Important Information for Investors and Shareholders

The Business Combination will be submitted to shareholders of Kensington for their consideration. In connection with the Business Combination, Kensington intends to file a Registration Statement with the SEC (the “Registration Statement”), which will include a proxy statement/prospectus and certain other related documents, which will serve as both the proxy statement to be distributed to shareholders of Kensington in connection with its solicitation for proxies for the vote by its shareholders in connection with the Business Combination and other matters to be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued to securityholders of Kensington and securityholders of Nth Cycle in connection with the completion of the Business Combination. After the Registration Statement is declared effective, Kensington will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the Business Combination. This press release is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that Kensington will send to its shareholders in connection with the Business Combination.

INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ, WHEN AVAILABLE, THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION AND THE PARTIES TO THE BUSINESS COMBINATION. Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed with the SEC free of charge at www.sec.gov. The definitive proxy statement/final prospectus (if and when available) will be mailed to shareholders of Kensington as of a record date to be established for voting on the Business Combination. Shareholders of Kensington will also be able to obtain copies of the proxy statement/prospectus without charge, once available, by directing a request to: Kensington Capital Acquisition Corp. VI, 1400 Old Country Road, Suite 301, Westbury, NY 11590.

Participants in the Solicitation

Kensington and its directors, executive officers, and other members of management, and consultants, under SEC rules, may be deemed participants in the solicitation of proxies from Kensington’s shareholders with respect to the Business Combination. Information about the directors and executive officers of Kensington is set forth in its Registration Statement on Form S-1, as amended. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Registration Statement and other relevant materials to be filed with the SEC regarding the Business Combination and related transactions when they become available. Stockholders, potential investors and other interested persons should read the Registration Statement carefully when it becomes available before making any voting or investment decisions. When available, these documents can be obtained free of charge from the sources indicated above.

Nth Cycle, its directors, executive officers, other members of management, and employees, under SEC rules, may be deemed participants in the solicitation of proxies of Kensington’s shareholders in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination will be included in the Registration Statement when available.

No Offer or Solicitation

This document shall not constitute a “solicitation” as defined in Section 14 of the Securities Exchange Act of 1934, as amended. This document shall not constitute an offer to sell or exchange, the solicitation of an offer to buy or a recommendation to purchase, any securities, or a solicitation of any vote, consent or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. No offering of securities in the Proposed Business Combination shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Investor Relations Contact:
Gateway Group
Georg Venturatos, Patrick Hall
949-574-3860
[email protected] 

Media Relations Contact:
Gateway Group
Zach Kadletz
949-574-3860
[email protected] 

Kensington:
Dan Huber
Chief Financial Officer
703-674-6514
[email protected] 

SOURCE Kensington Capital Acquisition Corp. VI

Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

Financing led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners and KCap Biotechnology Fund and all existing investors

Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout 

SAN DIEGO, July 22, 2026 — Crystalys Therapeutics Inc. (‘Crystalys’ or ‘the Company’), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced the closing of an oversubscribed $130 million Series B financing to support the late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout. The financing was led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners and KCap Biotechnology Fund and all existing investors – Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund. 

Dotinurad’s clinical development program includes two ongoing Phase 3 registration-directed trials, RUBY and TOPAZ, as well as the ongoing Phase 2 AMETHYST study, collectively designed to evaluate dotinurad across a broad spectrum of patients with gout, including those with limited treatment options. The proceeds from the financing are expected to support ongoing clinical development of dotinurad, commercialization preparation activities and provide operational runway through multiple anticipated clinical and regulatory milestones.

“We are delighted to have the support of this strong syndicate of new investors and all our existing investors as we advance dotinurad through late-stage clinical development and into commercialization preparation,” said James Mackay, Ph.D., President and Chief Executive Officer of Crystalys Therapeutics. “This financing strengthens our ability to advance our RUBY, TOPAZ and AMETHYST studies and positions Crystalys to achieve multiple important clinical and regulatory milestones and commercial readiness as we work to bring a potentially best-in-class treatment option to patients living with gout. “

“We are pleased to support Crystalys at this important stage of growth as the company continues to advance dotinurad,” said Kevin Li, Partner, Frazier Life Sciences. “The company has built a strong foundation around a late-stage asset with the potential to address significant unmet needs in gout, supported by an experienced leadership team. We believe Crystalys is well positioned to potentially create meaningful impact for patients and also believe in the company’s ability to work towards commercialization.”

About Gout

Gout is the most common form of inflammatory arthritis. It is a condition that is very debilitating for patients and characterized by sudden, severe attacks of pain, swelling, redness and tenderness in one or more joints. This disease arises from excess uric acid in the body, known as ‘hyperuricemia,’ which causes buildup of uric acid crystals and inflammation, which can lead to tophaceous gout in people with chronic or undertreated disease. Despite available therapies that aim to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors and last-line uricase therapy. Currently, no suitable second-line options exist in the U.S. or E.U., leaving a critical unmet need for patients who fail to respond to first-line treatments.

About Crystalys Therapeutics

Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company’s lead candidate, dotinurad, is a next-generation, once daily, oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, the Philippines, Taiwan and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY, TOPAZ studies and the Phase 2 AMETHYST study evaluating the safety and efficacy of dotinurad in patients with gout.

For more information, visit www.crystalystx.com/ and follow us on X and LinkedIn.

SOURCE Crystalys Therapeutics

Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva’s lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors

SINGAPORE, July 22, 2026Tikva Allocell Pte. Ltd. (“Tikva”), a biotechnology company developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors, today announced the closing of an $8 million Series A financing led by Kantharos Capital.

Proceeds will fund IND-enabling activities and a planned year-end 2026 Investigational New Drug (IND) submission for TAVST01, Tikva’s lead candidate for B7-H3-positive solid tumors. Subject to regulatory clearance, the company plans to initiate a Phase 1 clinical trial in patients with advanced B7-H3-positive cancer at sites in Singapore and the United States.

TAVST01 targets B7-H3, a protein expressed across a broad range of difficult-to-treat solid tumors, including lung, breast, prostate, pancreatic, and pediatric cancers. Unlike conventional donor-derived cell therapies, which a patient’s immune system often clears before they can work, TAVST01 is built from Epstein-Barr virus (EBV)-specific T cells – immune cells the body naturally sustains – and is engineered to resist that rejection, with preclinical potential both to kill tumor cells directly and to remodel the immunosuppressive microenvironment that has limited cell therapies in solid tumors. That durability is no accident: almost everyone carries EBV from a past infection the immune system never fully clears, so the body keeps a standing population of these virus-specific T cells on patrol for years – exactly the staying power that donor-derived cell therapies have struggled to achieve.

“Cell therapy has transformed the treatment of blood cancers but has repeatedly stalled at the solid-tumor door – the donor cells either fail to persist or are eliminated by the patient’s immune system before they can act,” said Dr. Ivan Horak, Founder and Chief Executive Officer of Tikva Allocell. “We started from a different place: a virus-fighting T cell the body naturally sustains, armed to seek out B7-H3 and engineered to withstand the rejection that defeats most donor-derived approaches, with minimal gene editing. With this financing, we are well positioned to complete IND-enabling studies and advance TAVST01 toward its planned IND submission, bringing us closer to delivering a scalable, readily available, and potentially transformative cell therapy for patients with solid tumors.”

Tikva’s therapies are built on the ALLO SerpinB9 EBVST platform — an allogeneic, virus‑specific T‑cell technology licensed exclusively from Baylor College of Medicine and further enhanced through Tikva’s proprietary protein‑engineering strategies. These cells are equipped with a B7‑H3–targeting receptor and an optimized form of SerpinB9, a natural inhibitor of granzyme B, the enzyme immune cells use to kill their targets. Because a patient’s immune system would normally attack donor cells using granzyme B, the SerpinB9 “armor” enables Tikva’s cells to resist rejection and remain active. At the same time, the approach minimizes graft‑versus‑host disease (GvHD) with only minimal gene editing.

“Our investment reflects strong conviction in both Tikva’s science and its leadership team,” said Terence Tan, Managing Partner at Kantharos Capital. “Tikva is addressing fundamental challenges that have constrained allogeneic cell therapies, and we believe its ALLO SerpinB9 EBVST platform can extend the reach of cell therapy to solid-tumor patients who today have limited options. We look forward to supporting the company toward IND submission and clinical evaluation.”

About Tikva Allocell
Tikva Allocell Pte. Ltd., headquartered in Singapore, is a biotechnology company developing engineered, allogeneic (donor‑derived) cell therapies for solid tumors. The company’s pipeline is built on the ALLO SerpinB9 EBVST platform—an allogeneic, virus‑specific T‑cell technology licensed exclusively from Baylor College of Medicine and enhanced through Tikva’s proprietary protein‑engineering strategies. This platform integrates tumor‑targeting receptors such as B7‑H3 with an optimized form of SerpinB9 to help donor‑derived T cells resist granzyme‑B–mediated immune rejection, persist longer, and minimize graft‑versus‑host disease with minimal gene editing.

Tikva’s scientific foundation is rooted in decades of research at Baylor College of Medicine by Dr. Malcolm Brenner, Dr. Cliona Rooney, and Dr. Helen Heslop—leaders in virus‑specific T‑cell biology—who co‑founded Tikva with CEO Dr. Ivan Horak and serve as scientific advisors. The company’s lead program, TAVST01, is an off‑the‑shelf, B7‑H3‑targeted EBV‑specific T‑cell therapy in IND‑enabling development for a planned year‑end 2026 IND submission. TAVST01 is designed for patients with B7‑H3‑positive solid tumors, including lung, breast, prostate, pancreatic, and pediatric cancers, and has a preclinical profile that may support lymphodepletion‑free administration, repeat dosing, and combination strategies. For more information, visit www.tikvaallocell.com.

About Kantharos Capital
Kantharos Capital is a boutique private equity firm founded by a family office with more than three decades of venture investing experience across Silicon Valley, China, and Singapore. It pairs institutional discipline with the patience and long-term perspective of family capital to help founders build enduring businesses.

Contacts
Tiberend Strategic Advisors, Inc.
Investor Relations
David Irish
+1-231-632-0002
[email protected] 

Media Relations
Casey McDonald
+1-646-577-8520
[email protected] 

SOURCE Tikva Allocell